» Articles » PMID: 36134201

Personalized Targeted Therapeutic Strategies Against Oral Squamous Cell Carcinoma. An Evidence-Based Review of Literature

Overview
Publisher Dove Medical Press
Specialty Biotechnology
Date 2022 Sep 22
PMID 36134201
Authors
Affiliations
Soon will be listed here.
Abstract

Oral squamous cell carcinoma (OSCC) is the most common type of malignant tumor in the head and neck, with a poor prognosis mainly due to recurrence and metastasis. Classical treatment modalities for OSCC like surgery and radiotherapy have difficulties in dealing with metastatic tumors, and together with chemotherapy, they have major problems related to non-specific cell death. Molecular targeted therapies offer solutions to these problems through not only potentially maximizing the anticancer efficacy but also minimizing the treatment-related toxicity. Among them, the receptor-mediated targeted delivery of anticancer therapeutics remains the most promising one. As OSCC exhibits a heterogeneous nature, selecting the appropriate receptors for targeting is the prerequisite. Hence, we reviewed the OSCC-associated receptors previously used in targeted therapy, focused on their biochemical characteristics and expression patterns, and discussed the application potential in personalized targeted therapy of OSCC. We hope that a better comprehension of this subject will help to provide the fundamental information for OSCC personalized therapeutic planning.

Citing Articles

Exploring the role of oral bacteria in oral cancer: a narrative review.

Mivehchi H, Eskandari-Yaghbastlo A, Pour Bahrami P, Elhami A, Faghihinia F, Nejati S Discov Oncol. 2025; 16(1):242.

PMID: 40009328 PMC: 11865422. DOI: 10.1007/s12672-025-01998-2.


Novel Predictive Biomarkers in the Head and Neck Squamous Cell Carcinoma (HNSCC).

Miniuk M, Reszec-Gielazyn J, Bortnik P, Borsukiewicz A, Mroczek A J Clin Med. 2024; 13(19).

PMID: 39407936 PMC: 11477133. DOI: 10.3390/jcm13195876.


Adjunctive Impact of Mitochondria-Targeting Antibiotics for Cancer Stem Cells of Oral Squamous Cell Carcinoma: Proposal for a Novel Approach in Resistant Cases.

Amiri M, Abbasi H, Hamedani S, Daneste H J Dent (Shiraz). 2024; 25(3):190-191.

PMID: 39371952 PMC: 11452599. DOI: 10.30476/dentjods.2024.102852.2397.


An Integrated Approach of Network Pharmacology, Bioinformatics, Molecular Docking, and Experimental Verification Uncovers as the Potential Medicine of Prognosis Improvement for Oral Squamous Cell Carcinoma.

Chen J, Zhang X Curr Pharm Des. 2024; 31(5):391-412.

PMID: 39289945 DOI: 10.2174/0113816128328547240827045955.


Triple Positive Oral Squamous Cell Carcinoma Patients Predict Poor Survival Outcomes: Multiple Factor Positivity Warrants the Need for Modified Treatment Approaches.

Jain P, Sultania M, Muduly D, Chaudhary I, Ghalige H, Patro S J Maxillofac Oral Surg. 2024; 23(4):923-934.

PMID: 39118932 PMC: 11303734. DOI: 10.1007/s12663-024-02186-5.


References
1.
Kawabata H . Transferrin and transferrin receptors update. Free Radic Biol Med. 2018; 133:46-54. DOI: 10.1016/j.freeradbiomed.2018.06.037. View

2.
Christensen J, Burrows J, Salgia R . c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005; 225(1):1-26. DOI: 10.1016/j.canlet.2004.09.044. View

3.
Chai A, Lim K, Cheong S . Translational genomics and recent advances in oral squamous cell carcinoma. Semin Cancer Biol. 2019; 61:71-83. DOI: 10.1016/j.semcancer.2019.09.011. View

4.
Chen H, Deng J, Yao X, He Y, Li H, Jian Z . Bone-targeted erythrocyte-cancer hybrid membrane-camouflaged nanoparticles for enhancing photothermal and hypoxia-activated chemotherapy of bone invasion by OSCC. J Nanobiotechnology. 2021; 19(1):342. PMC: 8549398. DOI: 10.1186/s12951-021-01088-9. View

5.
Austin L, Kang B, Yen C, El-Sayed M . Plasmonic imaging of human oral cancer cell communities during programmed cell death by nuclear-targeting silver nanoparticles. J Am Chem Soc. 2011; 133(44):17594-7. PMC: 4721227. DOI: 10.1021/ja207807t. View